Biocytogen Closes Series D+ at CNY790 Mn

According to VCBeat, Beijing-based biotechnology platform Biocytogen announced the close of a CNY790 million Series D+ funding round led by CMB International with participation from SDIC Venture Capital, China Life Investment Holding Company, 3E Bioventures, Cowin Capital, and PICC Capital Equity.

"The funds raised in this round will strongly support the project of fully-human antibodies using 'mice models'", Dr. Shen Yuelei, the Chairman and CEO of Biocytogen, said, "With the development of this project, Biocytogen will cooperate with many pharmaceutical companies at home and abroad to accelerate the process of innovative drug R&D to market for the benefit of patients."

Biocytogen provides one-stop solutions for next-generation drug development, from target to IND application to the global biomedical communities. Empowered by its cutting-edge gene-editing technologies and state-of-art animal facility, Biocytogen developed an integrated platform for efficient antibody drug discovery.

Biocytogen has a comprehensive portfolio of products and services, covering in vivo/in vitro preclinical services, animal model generation, fully human antibody (via RenMab™ Mouse), therapeutic antibody discovery and development services, CMC/CDMO, and regulatory affairs support. 

With its strategic transformation to a biotech company, Biocytogen will focus more on innovative antibody drug development in the future. With the large-scale antibody drug development project using 'mice models', Biocytogen will join hands with global partners to accelerate the development of new drugs together.

Headquartered in Beijing, Biocytogen has branches in Haimen and Shanghai in China, and Boston in the US. Its wholly-owned subsidiary Eucure Biopharma focuses on clinical development.

Founded in 2016, SDIC Venture Capital is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market-driven governance structure. SDICVC currently manages four funds, with AUM at 14 billion yuan.

China Life Investment Holding is an investment platform for China Life’s magnificent vision in the healthcare sector, focusing on investment opportunities of premium-quality companies along the industry chain of healthcare. It is committed to giving full play to the driving role of commercial insurance, and deeply promoting the integration and development of healthcare and insurance service.